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Kinetic characterisation 
and inhibitor sensitivity of Candida 
albicans and Candida auris 
recombinant AOX expressed 
in a self‑assembled proteoliposome 
system
Alice C. Copsey1,4, Mario R. O. Barsottini1,4, Benjamin May1,2, Fei Xu1,3, Mary S. Albury1, 
Luke Young1 & Anthony L. Moore1*
Candidemia caused by Candida spp. is a serious threat in hospital settings being a major cause of 
acquired infection and death and a possible contributor to Covid‑19 mortality. Candidemia incidence 
has been rising worldwide following increases in fungicide‑resistant pathogens highlighting the need 
for more effective antifungal agents with novel modes of action. The membrane‑bound enzyme 
alternative oxidase (AOX) promotes fungicide resistance and is absent in humans making it a desirable 
therapeutic target. However, the lipophilic nature of the AOX substrate (ubiquinol‑10) has hindered its 
kinetic characterisation in physiologically‑relevant conditions. Here, we present the purification and 
expression of recombinant AOXs from C. albicans and C. auris in a self‑assembled proteoliposome (PL) 
system. Kinetic parameters  (Km and  Vmax) with respect to ubiquinol‑10 have been determined. The PL 
system has also been employed in dose–response assays with novel AOX inhibitors. Such information 
is critical for the future development of novel treatments for Candidemia.
Candidemia is a major cause of morbidity and mortality in the health care system causing a serious public health 
risk and concomitant economic burden. The incidence of invasive fungal infections caused by Candida spp. has 
increased significantly since the 1980’s, especially amongst those who are immunocompromised and in need 
of critical care due to underlying  illness1. As part of the normal microbiota of the host mucus membranes and 
gastrointestinal and genitourinary tracts in a healthy host the fungus is largely commensal, causing little or no 
damage. However, as an opportunistic pathogen when the host’s immune system is compromised these yeasts 
can adapt causing both superficial and life threatening infections. Consequently, they have become one of the 
major agents of hospital acquired infection. Whilst more than 17 different Candida spp. are known to cause 
human infection, Candida albicans is the most frequently isolated Candida spp. in a clinical setting, and is widely 
accepted as being the most pathogenic Candida2–4. C. albicans infections are the fourth most common cause of 
hospital acquired systemic infections in the United States with a mortality rate as high as 50%5.
More recently the proportion of infections caused by C. albicans relative to other species has decreased. The 
significant increase in non-albicans infections seen in recent years is largely the result of increasing use of pro-
phylactic antifungal agents such as fluconazole, a drug commonly used to treat  candidaemia6. One such species 
of concern is Candida auris which in comparison to C. albicans has shown reduced susceptibility to fluconazole 
in over 90% of  cases7. Of particular concern is the finding that C. auris seems not only resistant to fluconazole, 
but disturbingly also resistant to the 3 main classes of antifungal drugs; azoles, echinocandins and polyenes. This 
species was first isolated form the ear of a Japanese patient in 2009 and is now a wide-spread pathogen which 
has been isolated from patients in more than 30 countries spanning all continents except  Antarctica7–9, and 
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alarmingly now in the UK (2016)10. C. auris infection is associated with a high mortality rate and therapeutic 
 failure10–15. Of particular importance is the suggestion that patients hospitalised in ICU for Covid-19 tend to share 
similar risk factors and underlying co-morbities with C. auris  infections16. The continuing Covid-19 pandemic 
may therefore provide ideal conditions for further outbreaks of C. auris infection in ICUs and indeed current 
Covid-19 patient mortality may in some way have been partly due to a contribution from C. auris  infection16. 
Given the resistance of C. auris to conventional anti-fungal treatments it is therefore even more imperative that 
new drugs to treat this fungus are urgently developed.
Within organisms such as C. auris and albicans, the alternative oxidase (AOX) plays a very key role in 
facilitating continued respiratory activity and tends to be activated by stress conditions such as the presence 
of antifungals or oxidative  inductors17,18. AOX is a cyanide and antimycin-resistant monotopic di-carboxylate 
protein which acts as terminal respiratory  pathway19,20. AOX is ubiquitous not only amongst the plant kingdom 
but also found in some important plant and mammalian fungi and protist  pathogens18. Of particular importance 
is the finding that AOXs are widespread amongst human parasites such as Trypanosoma brucei (which causes 
African Sleeping Sickness)20,21, intestinal parasites such as Cryptosporidium parvum22 and Blastocystis hominis23 
and opportunistic human pathogens such as Candida spp.24. There is increasing evidence to suggest that AOX 
induction leads to drug tolerance in the majority of these species, and inhibition of AOX has been reported to 
potentiate the inhibition of the growth of C. albicans by  fluconazole15,24, however to date potent and specific 
drugs targeted at the AOX in these organisms are yet to be achieved. Such results highlight the importance of 
discovering new drugs that are both well tolerated and have clearly defined biochemical targets such as the AOX.
In an attempt to investigate the extent to which Candida AOX proteins are sensitive to some novel AOX 
inhibitors we have utilised a self-assembled proteoliposome (PL) system described by Jones et. al 25. in which 
Candida AOX is used as the sole ubiquinol  (Q10H2) oxidising agent. In our system PLs contain bacterial NADH 
dehydrogenase (NDH-2), ubiquinone  (Q10), and an AOX to recycle ubiquinol to ubiquinone. NDH-2 is present 
in excess, such that AOX is completely rate determining and consequently the  Q10 pool is kept fully reduced 
under steady-state catalysis. We demonstrate that only TAO retains enzymatic activity following solubilisation 
from Escherichia coli membranes, but activity for both Candida spp. is restored following incorporation into 
PLs confirming the importance of a lipid environment to retain structural integrity of purified AOXs. We have 
utilised the self-assembled  Q10PL system to compete some novel AOX inhibitors against physiologically relevant 
quinol substrates thereby providing properly defined and robust inhibitor dissociation constants. We believe 
that such inhibitors and their analogues will prove important for the future design of anti-fungal compounds 
with a novel mode of action, namely targeted at the AOX which is distinct from any existing anti-fungals com-
mercially available.
Results
To analyse the kinetic parameters of a variety of purified AOX proteins, a PL system catalysing NADH:O2 was 
utilised in which the ubiquinone pool was maintained reduced by an NADH dehydrogenase (NDH-2 from 
Caldalkalibacillus thermarum) and ubiquinol was reoxidised by AOX (Fig. 1A). His-tagged NDH-2 was expressed 
in E. coli C41 and purified to homogeneity as described by Heikal et al.26 as detailed in Materials and Meth-
ods. Figure 1B indicates that NDH-2 purified protein ran as a single band on SDS-PAGE running close to the 
predicted molecular mass of 44 kDa as described by Heikal et al.25 and typically possessed a specific activity of 
100 µmol NADH oxidised  min−1 mg  protein−1 (Fig. 1C). Twin strep-tagged T. brucei, C. albicans and C. auris AOX 
were purified as outlined in Materials and Methods and visualized through both Western blotting using anti-
strep antibodies and coomassie staining. Figure 1B indicates the purity of these proteins and, as predicted from 
their molecular weights, C. albicans AOX2 and C. auris AOX run higher than that of TAO due to the presence 
of a fungal specific sequence  insertion27. All membrane-bound AOXs displayed comparable activities (Fig. 1C). 
However what is particularly noteworthy is the finding that even though only single bands were visualised for 
both Candida spp. no quinol oxidase activity could be detected for the purified protein with either species in 
contrast to the high activity observed with TAO.
Measurement of AOX kinetic parameters. PLs were created by incorporating approximately 50 µg of 
AOX protein in the presence of  Q10 ranging from 0 to 100 nmol whereas NDH-2 protein was added directly to 
the activity assay at a concentration which ensured AOX remained rate limiting and this was achieved by creat-
ing the PLs in the presence of AOX and titrating AOX activity with exogenous NDH-2 until maximal rates were 
achieved for a pre-set ubiquinol concentration (see Fig. 2A and Supplementary Fig. 1). As AOX was incorpo-
rated during the preparation of the PLs, it is distributed on both sides of the membrane whereas since NDH-2 is 
added during the assay its location is restricted to the outer surface only.
We confirmed that NDH-2 maintained the Q-pool in a reduced state through the simultaneous measurement 
of oxygen consumption and the steady-state redox poise of the ubiquinone pool using an Oroboros NextGen-
O2k high resolution respirometer fitted with a Q-electrode  system28 the results of which are shown in Fig. 2B. 
It is apparent from Fig. 2B that in the absence of NDH-2 the small increase in the Q-redox poise on addition 
of NADH is due to a direct interaction of NADH with the glassy carbon electrode. The subsequent addition of 
aliquots of NDH-2, however, results in a rapid and complete reduction of the Q-pool to approximately 98% which 
is associated with a negligible oxygen consumption rate. Following the addition and engagement of 3 aliquots 
of purified TAO at this NDH-2 concentration, marked and measurable respiratory rates are observed and the 
Q-pool reduction level has fallen to 93%, 80 and 60% respectively. The subsequent addition of 1 µM ascofuranone 
(AF) completely inhibits respiration and returns the Q-pool to its fully reduced state confirming that the AOX 
was fully engaged under these conditions and furthermore that all oxygen consumption was due to AOX activity.
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Of particular importance was the finding that incorporation of the C. albicans and C. auris AOXs into 
liposomes, following the rationale described for the development of this  technique25,29,30 readily restored enzy-
matic activity which had been lost after solubilisation and purification. Figure 2C–E shows the Michaelis–Menten 
curves for AOXs from C. albicans (AOX2), C. auris and TAO  respectively25,29. Ubiquinone concentrations in 
the liposome membrane were calculated assuming that 1 mg of phospholipid occupies 1 µL and hence 1 nmol 
of quinone in 1 mg of phospholipid corresponds to 1  mM29,30. In all cases typical Michaelis–Menten Kinetics 
were observed for all AOXs (Fig. 2C–E), the derived Km and Vmax values for each of these proteins being sum-
marised in Fig. 2F.
It is apparent from Fig. 2F that all AOX proteins possess a similar Km with respect to  Q10 ranging from 4.6 to 
7.3 mM whereas Vmax values varied between 251–578 µmol NADH  min−1  mg−1. Interestingly, the highest Vmax 
(or kcat) was observed with C. albicans AOX2 at 578.0 µmol NADH  min−1  mg−1 (404  s−1) followed by TAO at 
251.6 µmol NADH  min−1  mg−1 (146  s−1) and C. auris AOX at 166.8 µmol NADH  min−1  mg−1 (108  s−1). Finally, 
Fig. 2F shows the catalytic efficiency or pseudo second order rate constant (kcat/Km), which reflects both substrate 
binding and catalytic events, for all of the AOXs incorporated into PLs. Km, Vmax and kcat values are statistically 
similar between all AOXs, however kcat/Km differed significantly between each one (p < 0.001). These results 
suggest that C. albicans AOX2 has the best ability to convert substrate to product being more than double that 
of TAO and 4 times greater than that of C. auris AOX.
AOX inhibitor titrations. The great advantage of the PL system originally described by the Hirst 
 laboratory25,29 and used in this study is that AOX inhibitors can be titrated against physiologically relevant qui-
nol substrates thereby providing properly defined and robust inhibitor dissociation constants. In this study we 
titrated all 3 oxidases in self-assembled PL system against Ascofuranone (AF), colletochlorins B and D (CB 
and CD respectively) and compared the results to that with SHAM (salicylhydroxamic acid), the most widely 
used AOX inhibitor. AF, CB and CD have previously been shown to behave as mixed type inhibitors against the 
Trypanosomal protein, with ascofuranone being effective against trypanosomes in vivo31 (for structures see Sup-
plementary Fig. 2). A  Q10 concentration of 10 mM was selected as being the closest concentration to that within 
the mitochondrial membrane, thereby approximating the effects of these inhibitors within a mitochondrial envi-
Figure 1.  A proteolipisome system for the measurement of AOX kinetics. (A) PLs suitable for kinetic studies 
were prepared by inserting Ubiquinone-10  (Q10) and bacterially-expressed AOX proteins into phospholipid 
 vesicles26. After PL preparation, NDH-2 was added externally to bind to the membrane of the PLs for oxidation 
of the electron donor NADH and subsequently  Q10. Drawn with Microsoft Powerpoint 2016. (B) AOX and 
NDH-2 proteins were purified to homogeneity from bacterial membranes. Samples of total protein (1), insoluble 
(2) and soluble membrane fractions (3) and purified protein (4) were resolved by SDS-PAGE and visualised 
using immunoblotting (1–4) or coomassie blue staining; NDH-2 (5) TAO (6), C. albicans (7), C. auris (8). (C) 
Specific activity of membrane-bound AOX was detrmined by measurement of oxygen uptake in a Oroboros 
Q2k oxygraph. Specific activity of the purified AOX proteins was determined by monitoring the change of 
absorbance at  A278nm on oxidation of 100 nmol  Q1H2 by the oxidase and expressed as µmol.  Q1H2  min−1  mg−1. 
The specific activity of NDH-2 was determined by monitoring the change of absorbance at  A340nm on oxidation 
of 1 mM NADH and expressed as µmol. NADH oxidised  min−1  mg−1. Note that zero activity for C. albicans and 
C. auris AOX was detectable (ND). Original gels and blots are shown in Supplementary Fig. 4.
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ronment. In this case excess NDH-2 was incorporated into the PLs alongside AOX, and not added externally, in 
order to simplify the experimental setup and minimize handling times during dose–response assays.
Literature values for the turnover of NDH-2 and TAO are somewhat comparable, typically within the region 
of 15–200  s−126,32,33 and therefore to ensure that AOX proteins were rate-limiting during  IC50 measurements, PLs 
were created with a molar ratio of 400:1 NDH-2:AOX. Such a high ratio ensures that the Q-pool is maintained 
highly reduced and that the AOX is the rate-limiting step in the system.
It is apparent from Fig. 3 that the three inhibitors tested were active against all of the three AOX proteins in the 
sub-micromolar range—much lower concentrations than SHAM which is effective only at millimolar concentra-
tions. Indeed, SHAM is such a poor inhibitor that the high concentrations required for inhibition interfered with 
NADH absorbance readings and hence we resorted to oxygen consumption measurements to determine SHAM 
 IC50 values. For the three AOX proteins, CB displayed the lowest  IC50, followed by ascofuranone and CD.  IC50 
values for TAO were significantly lower than those for C. albicans AOX2 and C. auris AOX (Fig. 3E). Finally, 
the selectivity of ascofuranone, CB and CD towards all AOXs was evaluated in PLs containing only NDH-2, in 
which case DCPIP was used as an electron acceptor. Negligible effect of the inhibitors on NDH-2 up to 2.5 µM 
was detected (Supplementary Fig. 3).
Figure 2.  Kinetic characterization of AOX proteins incorporated into proteoliposomes with respect to 
ubiquinol-10  (Q10H2). (A) The rates of  Q10H2 oxidation by bacterially-expressed AOX were calculated at 
increasing NDH-2 concentrations. The reaction was monitored spectrophotometrically by the oxidation of 
NADH by NDH-2 at  A340 nm. Each bar shows the mean value of technical duplicates (diamonds). The point 
at which TAO AOX becomes rate limiting was determined and this concentration of NDH-2 protein was 
added to subsequent kinetic assays. (B) Concomitant measurements of oxygen consumption and redox poise 
of the Q pool in the PL system. PL prepared as described in the Methods section. The traces represent the  O2 
concentration (dot-dashed blue line) the  O2 consumption rate (continuous red line with values in nmol  O2 
 min−1 shown) and the redox poise of the Q pool (dashed black line). Serial additions of NADH, NDH-2, TAO 
and AF are indicated on top. (C–E)  Q10 Michaelis–Menten curve for AOXs. The assay was performed in 200 µL 
65 mM MOPS pH 7.5 with a starting concentration of 300 µM NADH. Each point (black dot) represents the 
mean value of individual PL preparations for which a different amount of  Q10 was added. Technical replicates 
are shown as gray diamonds. The rates of reaction were plotted against the  Q10 concentration in the membranes 
and fit to the Michaelis–Menten equation. Protein and  Q10 quantifications were performed as described in 
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Discussion
AOX is a respiratory protein which is gaining increasing interest in biotechnological applications such as a pos-
sible human therapeutic agent and as a molecular target for a novel class of antimicrobial agents. It is therefore 
imperative to determine relevant biochemical parameters for this enzyme which will guide the future rational 
design of novel therapies. One such example is the development of antifungal agents effective against drug-
resistant strains of C. albicans and C. auris which are major sources of hospital infections in the UK and world-
wide. With the prevalence of antifungal resistance being both substantial and growing, the development of new 
bioactive compounds is essential, with drugs which target the switch to more virulent forms of the fungi being 
a prime candidate. The high resistance of Candida biofilms to anti-fungal compounds, in particular azoles, is 
one such example with the biofilms being up to 1000 times more resistant than the less virulent yeast  forms34.
Studies aimed at preventing the switch from a yeast to the far more virulent hyphae form associated with inva-
sive candidemia have implicated AOX as a possible therapeutic target. These include both in vitro assays using C. 
albicans which show that AOX inhibition results in oxidative stress, a reduction in cellular proliferation and an 
increase in suscepitbilty to  fluconazole35,36; and multiple studies suggesting a role for AOX enzymes in activation 
of the cAMP-PKA signalling pathway, which is one of the signalling pathways controlling hyphae  formation37–40. 
In addition a recent in vivo study using a mouse systemic model of candidiasis caused by C. albicans reinforced 
the link between AOX expression and hypha  formation41. This study indicated that AOX enzymes are required 
for hypha formation upon inhibition of the classical repiratory system.
Considerable complication in the development of antifungal drugs is that the fungi are eukaryotic; this ren-
ders them harder to treat due to the obvious need to select pathogen-specific targets, and AOX is of particular 
interest due to its absence in mammalian electron transport chains. One challenge posed by AOX, however, is 
Figure 3.  Inhibitor dose response assays for AOX incorporated into proteoliposomes. (A–D) Dose–response 
assay with AF, CB, CD and SHAM against AOX proteins. The assay was performed in 200 µL 65 mM MOPS 
pH 7.5 with a starting concentration of 300 µM NADH. Points represent the mean value (darker shading) and 
individual replicates (lighter shading) of technical measurements and the continuous line is the best fit for 
a four-parameter sigmoid function. (E)  IC50 values determined from the data presented in Panels A–D. All 
measurements are the average of 3 biological replications ± SD. For each inhibitor, C. albicans and C. auris  IC50 
values which are significantly different from TAO (i.e., within columns) are marked with asterisks (* p < 0.002 
and ** p < 0.001). C. albicans and C. auris differ significantly from each other only for AF (p = 0.013).
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the fact that it is a monotopic membrane protein and its natural substrate is the highly hydrophobic ubiquinol-10 
which is present within the phospholipid bilayer. To the best of our knowledge we present for the first time the 
characterization of Candida AOX in a PL system which is a truer reflection of the hydrophobic environment 
of the mitochondrial membrane rather than using detergent-solubilised AOX and the hydrophilic ubiquinol-1 
analog. The advantage of the PL system is evident when one compares AOX catalytic rates before and after incor-
poration of pure protein into PLs. Indeed, the fungal AOXs presented here had no detectable enzymatic activity 
after removal of the bacterial membrane (Fig. 1C) which was promptly restored following incorporation into 
PLs (Fig. 2D,E). It is noteworthy that the enzymatic activity of pure AOX in solution is not a good predictor of 
enzymatic activity in the PL. Based on results obtained with pure (solubilised) protein, TAO has been considered 
to possess the highest  Vmax to date whereas fungal AOXs have shown notoriously low rates in  comparison42. 
However our results demonstrate that C. albicans and C. auris AOX can also possess high  Vmax values and indeed 
under appropriate conditions surpass that of TAO. Moreover, AOX turnover rates obtained here are comparable 
to those of other mitochondrial quinol oxidases (the cytochrome bc1 complex) and a quinone reductase (complex 
I) in PLs, namely 620  s−1 and 380  s−1,  respectively29,43.
Of particular importance with respect to the use of PLs is that the substrate concentration is not limited by 
its solubility in aqueous medium which has previously hindered the determination of the true kinetic param-
eters of  AOX43. Previous attempts at characterizing AOX have used the hydrophilic ubiquinol-1 analogue which 
can be used only up to ca. 600 µM before forming micelles.  Km values for  Q1 lie in the micromolar range of 
 concentrations33,42, however our results using PLs with the natural substrate  Q10 demonstrate that true  Km 
values for AOX are greater by 2 orders of magnitude namely 4–8 mM. The ubiquinol  Km value reported for the 
cytochrome bc1 complex (~ 10 µM) is, however, much lower than values for AOX, although it is not inconceiv-
able that such values are possibly underestimations since the partitioning of ubiquinol into the lipid phase was 
not taken into  consideration43. However, in a biological context this fits well with the AOX’s role within the 
mitochondria—having a significantly higher  Km for ubiquinol than that of the cyctochrome bc1 complex would 
mean that ubiquinol would preferentially bind to the latter, with the AOX only effectively being engaged as an 
overflow at time when the ubiquinol pool was highly  reduced21,33.
The interest in using AOX as a therapeutic target to treat both human and plant pathogens is  growing24,35–40, 
and a number of animal studies have implicated AOX for the treatment of human mitochondrial diseases using 
gene  therapy44–49. The work undertaken here has shown that all 3 ascofuranone derivatives tested are promising 
candidates with AOX inhibition with  IC50 values in the nM region, with colletochlorin B being the most effec-
tive. However, it should be noted that there is a significant decrease in efficacy of the compounds with the fungal 
AOX’s when compared to TAO, requiring a 250 fold increase in concentration. These values are reasonably con-
sistent with those seen against other fungal AOX’s50, which has largely been attributed to the decrease in size of 
the hydrophobic cavity in the fungal species when compared to TAO being problematic for inhibitor  egress42,51.
Novel drug-like molecules are therefore urgently required to translate the recent findings relating to AOX, its 
role in C. auris and it’s potential use as a therapeutic target for treating candidiasis particularly within a Covid-19 
setting. We conclude that the incorporation of AOX into the PL system serves as an important tool not only for a 
more accurate characterisation of AOX catalytic rates but more importantly such a system is required to translate 
novel drug design currently underway in laboratories across the world into effective therapies.
Materials and methods
Expression and purification of NDH‑2. NDH-2 protein expression and purification was based on the 
method of Heikal et al.26. Fresh E. coli C41 transformants carrying the plasmid pTRCndh2 were used to inoc-
ulate 10  ml starter cultures of L broth, supplemented with 100  µg   ml−1 ampicillin, for growth over-night at 
37 °C,180 rpm. Each 10 ml starter culture was used to inoculate 1 L of L-broth supplemented with 100 µg  ml−1 
carbenicillin for growth at 37 °C, 180 rpm. Once an  OD600 of 0.5 was reached expression of NDH-2 was induced 
by the addition of 1 mM isopropyl-beta-D-thiogalactopyranoside (IPTG). Once growth plateaued (typically OD 
of 1.5 to 1.9) cells were harvested by centrifugation at 7000 × g for 15 min at 4 °C, weighed, and resuspended in 
lysis buffer (50 mM Tris–HCl pH 7.5, 2 mM  MgCl2, EDTA free protease inhibitor cocktail (Roche)). The cells 
were lysed using two passes through a pre-cooled cell disruption system (Constant Systems Ltd) set to 30 kPa of 
pressure. The cell lysate was centrifuged for 15 min at 11,500 × g at 4 °C to collect cells debris and non-lysed cells.
To collect membranes, the supernatant was centrifuged for 60 min at 200,000 × g, 4 °C. Membranes were 
resuspended in 50 mM Tris HCl pH 8.0 at a concentration of 10 mg  ml−1 and solubilised by drop wise addition 
into an equal volume of solubilisation buffer (50 mM Tris HCl pH 8.0, 2% (w/v) n-octyl-β-D-glucopyranoside 
(OG), 4 mM imidazole, 150 mM NaCl, EDTA free protease inhibitor cocktail (Roche)) whilst stirring at 4 °C 
followed by 60 min rotation at 4 °C. Finally, the sample was centrifuged for 30 min at 200,000 × g, 4 °C to collect 
solubilized membranes.
NDH-2-His was purified by passage through a 5 ml HiTrap TALON Crude column attached to an ÄKTA 
FPLC (GE Healthcare Life Sciences). The column was equilibrated at a flow rate of 1 ml per minute in binding 
buffer (50 mM Tris–HCl pH 8.0, 1% (w/v) OG, 2 mM imidazole, 150 mM NaCl). Protein was bound to the col-
umn at a flow rate of 0.5 ml  min−1 and washed at a flow rate of 1 ml  min−1 until the absorbance at  A280 nm had 
returned to the baseline. Protein was eluted with elution buffer (50 mM Tris HCl pH 8, 150 mM NaCl, 400 mM 
imidazole and either 0.05% (w/v) n-Dodecyl β-maltoside (DDM) or 1% (w/v) OG). Peak fractions were col-
lected in a 96 well plate. Fractions containing NDH-2 were pooled, concentrated ~ tenfold via filtration using 
a 30 kDa weight cut off spin concentrator, supplemented with 10% glycerol and protease inhibitors, aliquoted, 
flash-frozen in liquid nitrogen and stored at − 80 °C. NDH-2 activity rates were measured pre and post freezing.
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NDH‑2 activity assay. The specific activity of the enzyme was measured spectrophotometrically by meas-
uring the oxidation of NADH at  A340 nm. The enzyme was diluted 1 in 50 in 50 mM MOPS pH 7.5 containing 
250 µM  Q1 and 300 µM NADH. Typical activity measurements were approximately 100 µmol NADH oxidized 
 min−1  mg−1 NDH-2.
AOX plasmid construction. The AOX from T. brucei, C. albicans and C. auris (GenBank accession num-
bers: AB070617, AF116872 and XP_018165728 respectively), lacking the mitochondrial targeting sequences (24, 
26 and 24 residues respectively), were expressed in a modified version of pET15b, first described by Fedor et. 
al 29. in which the 6xHis tag was replaced with a twin-strep tag. Gene constructs were synthesised with codon 
optimization for expression in E. coli (GenScript, Piscataway, NJ), and contained NdeI and BamHI restriction 
endonuclease sites at 5’ and 3’ ends respectively, for insertion into the pET15b.TS expression vector. The result-
ing plasmids were named pTS.TAO, pTS.CalbAOX2 and pTS.CaAOX.
AOX‑strep protein expression and membrane isolation. Over-expression of AOX was carried out 
in E. coli strain  FN10232. There are two AOX genes in C. albicans, AOX1 and AOX2, whilst the former is con-
stitutively expressed, expression of AOX2 is dependent on the growth stage and can be induced by inhibition of 
complex III or IV of the classical respiratory system. AOX2 was selected for these experiments.
AOX-strep was expressed in E. coli as described in Kido et. al.33. The protocol described was followed except 
for the following adaptions: two 50 ml day cultures of K-broth (supplemented with 100 µg  ml−1 carbenicillin, 
100 µg  ml−1 kanamycin, 50 µg  ml−1 5-aminolevulinic acid (ALA), 0.2% (w/v) glucose and 50 µl per flask of 
metal mix (containing 0.5 g of  MgSO4·7H2O, 0.25 g of  FeSO4·7H2O, 0.25 g  FeCl3 per 10 ml total volume) were 
inoculated with 1 ml of over-night culture (Luria broth inoculated with a single bacterial colony, supplemented 
with 100 µg  ml−1 ampicillin, 100 µg  ml−1 kanamycin, and 50 µg  ml−1 ALA). Cultures were grown at 37 °C in 
a shaking incubator until  OD600 reached approximately 0.6. Cells were collected by centrifugation, washed to 
remove the majority of ALA and used to inoculate 4 × 1 L of K-broth (supplemented with 100 µg  ml−1 carbenicil-
lin, 100 µg  ml−1 kanamycin, 0.2% (w/v) glucose and 1 ml of metal mix) as described in the referenced protocol. 
The 4 L culture was incubated at 30 °C, 180 rpm, until  OD600 reached 0.6 at which point protein expression was 
induced by the addition of 25 µM IPTG. Cultures were grown over-night at 30 °C, 180 rpm for approximately 
13 h before harvesting cells by centrifugation at 7000 × g for 15 min, 4 °C. Cell pellets were resuspended on ice in 
65 mM MOPS (KOH) pH 7.5, 1 mM  MgSO4, 2.5 Units of benzonase plus protease inhibitors. The cells were lysed 
using two passes through a pre-cooled cell disruption system (Constant Systems Ltd) set to 30 kPa of pressure. 
The cell lysate was centrifuged for 15 min at 11,500 × g at 4 °C to collect cells debris and non-lysed cells followed 
by 60 min, 200, 000 × g at 4 °C to collect the membrane fraction.
AOX‑strep protein solubilisation and purification. Isolated membranes were resuspended in 65 mM 
Mops pH 7.5 at a concentration of approximately 10 mg  ml−1 and solubilised by drop wise addition into an equal 
volume of solubilisation buffer (65 mM MOPS (KOH) pH 7.5, 2% (w/v) fos-choline 12 (FC12), 400 mM  MgCl2, 
40% glycerol, with protease inhibitors) whilst stirring at 4 °C followed by 60 min rotation at 4 °C. The sample was 
centrifuged for 30 min at 200,000 × g, 4 °C to collect solubilized membranes.
AOX-strep was purified by passage through a 5 ml StrepTrap HP column attached to an ÄKTA FPLC. The col-
umn was equilibrated at a flow rate of 1 ml  min−1 in binding buffer (65 mM MOPS (KOH) pH 7.5, 1% (w/v) FC12, 
50 mM  MgSO4, 160 mM NaCl, 20% glycerol). Protein was bound to the column at a flow rate of 0.5 ml  min−1 
and washed at a flow rate of 1 ml  min−1 until the  A280 nm had returned to the baseline. Protein was eluted with 
elution buffer (65 mM MOPS (KOH) pH 7.5, 2.5 mM desthiobiotin, 0.042% DDM, 50 mM  MgSO4,160 mM 
NaCl, 20% glycerol), and peak fractions were collected in a 96 well plate. Fractions containing AOX were pooled, 
concentrated ~ tenfold via filtration using a 30 kDa weigh cut off spin concentrator, aliquoted, flash-frozen in 
liquid nitrogen and stored at − 80 °C.
AOX activity assay. The specific activity of the purified protein was measured spectrophotometrically by 
measuring the oxidation of  Q1H2 at  A278 nm. The activity was measured in 50 mM MOPS (KOH) pH 7.5 con-
taining 150 µM  Q1H2.
Western blotting. Proteins were separated by SDS-PAGE, transferred to nitrocellulose membranes, and 
visualised with the appropriate antibodies followed by HRP-conjugated secondary antibodies (DAKO, 1:2000). 
HRP activity was detected using Pierce ECL Western Blotting Substrate followed by exposure to Amersham 
Hyperfilm. Antibody dilutions used for Western blotting were: anti-AOX (AOA)52 1:1000 and anti-StrepII (IBA: 
2–1509-001) 1: 20,000. The anti-Strep antibody is conjugated directly to HRP.
Preparation of proteoliposomes. PLs were prepared exactly as described in previously published pro-
tocols using phospholipids; phosphatidylcholine, phosphatidylethanolamine and cardiolipin, mixed at a ratio of 
8:1:125,29. A typical preparation used a total of 10 mg phospholipids and 100 nmol of  Q10, both of which are essen-
tial for PL  activity50. The only modifications to the protocol were the detergent used to partially solubilise the 
phospholipid/Q10 mixture (0.5% DDM in our preparations) and the protein content of the phospholipid vesicles 
as follows. For  IC50 measurements, 5 µg of AOX protein and 500 µg of NDH-2 were incorporated into the phos-
pholipid vesicles. 100 nmol of  Q10 were added whilst preparing the liposome vesicles for  IC50 measurements.
For measurement of  Km and  Vmax 50 µg of AOX protein was incorporated into the phospholipid vesi-
cles. NDH-2 protein was omitted from the PL preparation and instead added directly to the activity assay 
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at a concentration to ensure the AOX was rate limiting. A typical preparation resulted in a ratio of 1:100:200 
AOX:phospholipid:NDH-2. Between 0 and 160 nmol of  Q10 were added whilst preparing the liposome vesicle 
for the measurement of  Km and  Vmax.
Quantification of protein,  Q10 and lipid incorporation into the phospholipids. Protein and  Q10 
quantification were performed as described in previously published  protocols29. The quantification of both pro-
tein (using the Amido black assay) and  Q10 (by HPLC) was performed after the completion of the experiments 
to ensure any loss of protein or  Q10 during PL preparation did not effect these measurements. Lipid content was 
determined using the AMES test as described in previously published  protocols25.
Activity measurements in proteoliposomes. Activity assays were carried out in solutions containing 
65 mM MOPS pH 7.5 and 300 µM NADH. AOX was inhibited, when required, by addition of AOX inhibitors 
at final concentrations ranging from 2.5 pM to 25 µM for all inhibitors except for SHAM where the highest con-
centration was 500 µM. The selectivity of those inhibitors was evaluated with PLs containing only NDH-2 for 
which 300 µM 2,6-dichlorophenolindophenol (DCPIP) was used in the reaction medium as an electron acceptor 
instead of AOX. Rates of NADH oxidation were measured spectrophotometrically at  A340 nm using a Multiscan 
Sky 96-well plate reader (Thermo Scientific) and baseline rates from the reaction components alone (i.e. in the 
absence of any enzyme) were subtracted. Additionally, SHAM dose–response assays were performed in the 
high resolution oxygraph Oroboros Q2k (NextGenO2k, Oroboros Inc.) at concentrations as high as 20 mM by 
monitoring the PL oxygen consumption rate. The Oroboros was selected for SHAM dose–response assays due to 
the absorbance spectrum of the compound overlapping with the NADH signal. All other assays were performed 
using the plate reader for high throughput and to reduce reagent use.
Ubiquinone redox poise measurement. Simultaneous measurement of oxygen consumption and the 
ubiquinol/ubiquinone ratio was performed in a Oroboros O2k with a glassy carbon and platinum  electrodes28 
in 65 mM MOPS (KOH) pH 7.5 and 2 µM  Q2. 5 µL of a PL prepared without protein (only lipids and 100 nmol 
 Q10) were added in to the 2 ml measurement chamber followed by NADH, NDH-2, AOX and ascofuranone at 
concentrations described within the results section.
Statistics and reproducibility. Measurements were performed in technical triplicate and each experi-
ment was performed three independent times (e.g. distinct protein purification batches) unless otherwise stated 
and similar results were obtained each time. No data points were excluded from the analyses. Data fitting and 
plotting were performed with GraphPad Prism 7.0 (GraphPad Software Inc.). AOX Kinetic parameters and  IC50 
values were evaluated with the 2-way ANOVA test followed by Tukey’s multiple comparison test.
Data availability
All data used in this study are included within the main text or provided in the supplementary files. Source data 
for graphs/charts in the main figures is available in Supplementary Data 1. Any additional information and 
biological material described in the study is available from the corresponding authors upon request.
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